Nrx Pharmaceuticals Inc (NRXP)

$3.87 +0.01 (0.26%)
Market Cap 140.21M
Revenue (ttm) 1.23M
Net Income (ttm) -28.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,326.83%
Debt to Equity Ratio 0.00
Volume 668,700
Avg Vol 1,284,540
Day's Range N/A - N/A
Shares Out 36.23M
Stochastic %K 71%
Beta 2.19
Analysts Strong Sell
Price Target $39.67

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100,...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 254 6134
Address:
1201 N. Market Street, Suite 111, Wilmington, United States
texmade2
texmade2 Jul. 4 at 2:50 PM
$NRXP Target 1: 3.26 Support Below : at 3.64
0 · Reply
Outcomes
Outcomes Jul. 4 at 9:47 AM
$IBRX $MNKD $NRXP God bless America, from WellfleetCape Cod
1 · Reply
WhereDidAllTheMoneyGo
WhereDidAllTheMoneyGo Jul. 2 at 9:01 PM
$NRXP What's that big AH spike?
0 · Reply
the_franz
the_franz Jul. 2 at 8:33 PM
$NRXP Remember when David expected the NDA for NRX-100 in February, because Osmind data needs just some "crunching". Yeah, well, the company missed his expectations then and their own expectation (June 2026) now. But they failed their first self-imposed deadline which was "early 2024" (announced late 2023) I have put some money in some biotechs. I made profits, I made losses, but I cannot remember one company which announced a submission of a NDA for nearly three years. This is fishy as hell. The silence, why the self-imposed deadline has not been met, is deafening. Again! As someone who follows this company since its SPAC this pattern is well-known.
1 · Reply
Paulisdead
Paulisdead Jul. 2 at 6:57 PM
$NRXP If you’re evaluating NRXP as an investment, I can prepare a similar table for NRX-100, whose approval timeline has generated considerably more debate than KETAFREE’s. One important clarification before diving into the timeline: NRX-100 has undergone a significant evolution in its regulatory strategy. Earlier in development, NRX-100 referred primarily to intravenous ketamine for suicidal bipolar depression, often as the induction therapy preceding NRX-101. More recently, NRx has repositioned NRX-100 as a standalone preservative-free ketamine product with a broader depression indication supported by existing clinical trials and real-world evidence. That makes its regulatory history more complicated than KETAFREE’s.
2 · Reply
Paulisdead
Paulisdead Jul. 2 at 6:49 PM
$NRXP Asked ChatGPT How many times has the company with ticker symbol NRXP issued guidance that the fda would approve KETAFREE ketamine Answer: Based on the company’s public statements, the answer depends on how narrowly you define “guidance.” If you mean instances where NRx Pharmaceuticals (NASDAQ: NRXP) publicly indicated that it expected FDA approval of KETAFREE or provided a timeline implying approval, I can identify about five distinct guidance events: 1) Management repeatedly indicated it expected FDA action in Q2 2025 for its preservative-free ketamine program, based on its then-current regulatory strategy. That timeline ultimately slipped. 2) September 24, 2025 * After the FDA granted its Suitability Petition, the company stated this enabled immediate refiling of the ANDA and expressed confidence that KETAFREE would move toward market. <more in the reply to my post>
1 · Reply
fuctonfauci
fuctonfauci Jul. 2 at 5:45 PM
$NRXP If management says we're going to acquire the clinics and submit the NDA, then that's what we'll do. February, not Friday.
0 · Reply
TheRealBomb
TheRealBomb Jul. 2 at 1:29 PM
$NRXP @DavidBG That makes sense. The important part:. For now, the company is more than fully funded, allowing all operations and plans to go forward at full speed; and getting the ANDA to propel into profitability while awaiting the final NDA submission (NRX-100), and the running of the NRX-101/TMS trial (another massive revenue possibility) .
1 · Reply
DavidBG
DavidBG Jul. 2 at 1:19 PM
$NRXP It seems to me that NRXP is most likely still working with the FDA on a protocol for the Osmind data. That kind of back-and-forth can easily take more rounds than expected.
0 · Reply
systemish
systemish Jul. 2 at 4:53 AM
$NRXP So moving on from the missed deadline for NRX-100 NDA. It would be great to confirm that the initial order of KETAFREE is beyond initiating and is manufactured and waiting for its quarantine and testing so if approved more delays can be minimized. If not approved we’ll see all time lows and possibly bankruptcy. July going to be a wild ride.
1 · Reply
Latest News on NRXP
NRx Pharmaceuticals issues response to Kadima statements

2026-06-25T20:15:31.000Z - 8 days ago

NRx Pharmaceuticals issues response to Kadima statements

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

Jun 25, 2026, 4:01 PM EDT - 8 days ago

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Jun 25, 2026, 7:00 AM EDT - 9 days ago

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Kadima Neuropsychiatry Institute alleges NRx breached contract

2026-06-24T17:25:15.000Z - 10 days ago

Kadima Neuropsychiatry Institute alleges NRx breached contract

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

Jun 24, 2026, 1:18 PM EDT - 10 days ago

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

Jun 23, 2026, 11:05 AM EDT - 11 days ago

ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

ZETA

NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101

2026-06-22T11:18:34.000Z - 12 days ago

NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

Jun 22, 2026, 7:00 AM EDT - 12 days ago

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Jun 5, 2026, 8:50 AM EDT - 4 weeks ago

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option

Jun 4, 2026, 5:12 PM EDT - 4 weeks ago

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

2026-06-03T15:17:33.000Z - 4 weeks ago

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

Jun 3, 2026, 8:18 AM EDT - 4 weeks ago

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

NRx Pharmaceuticals announces common stock offering, no amount given

2026-06-02T20:05:59.000Z - 4 weeks ago

NRx Pharmaceuticals announces common stock offering, no amount given

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jun 2, 2026, 4:01 PM EDT - 4 weeks ago

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

May 28, 2026, 7:00 AM EDT - 5 weeks ago

NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

May 27, 2026, 7:00 AM EDT - 5 weeks ago

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 18, 2026, 8:00 AM EDT - 6 weeks ago

NRx Pharmaceuticals Earnings Call Transcript: Q1 2026

NRx Pharmaceuticals Quarterly report: Q1 2026

May 18, 2026, 8:00 AM EDT - 6 weeks ago

NRx Pharmaceuticals Quarterly report: Q1 2026

NRx Pharmaceuticals Earnings release: Q1 2026

May 18, 2026, 8:00 AM EDT - 6 weeks ago

NRx Pharmaceuticals Earnings release: Q1 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 18, 2026, 7:00 AM EDT - 6 weeks ago

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

May 14, 2026, 7:00 AM EDT - 7 weeks ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

NRx Pharmaceuticals initiated with a Buy at Lucid Capital

2026-05-13T10:11:36.000Z - 7 weeks ago

NRx Pharmaceuticals initiated with a Buy at Lucid Capital

NRx Pharmaceuticals gets FDA clearance to initiate NRX-101 trial

2026-05-07T18:39:21.000Z - 2 months ago

NRx Pharmaceuticals gets FDA clearance to initiate NRX-101 trial

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

May 7, 2026, 8:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

NRx Pharmaceuticals receives first commercial manufacturing order for ketamine

2026-05-05T13:49:41.000Z - 2 months ago

NRx Pharmaceuticals receives first commercial manufacturing order for ketamine

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

May 5, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

NRx Pharmaceuticals gets FDA feedback on ketamine program

2026-04-22T11:48:51.000Z - 2 months ago

NRx Pharmaceuticals gets FDA feedback on ketamine program

NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

Apr 22, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

White House shift on psychedelics positive for NRx, says D. Boral

2026-04-20T14:07:54.000Z - 2 months ago

White House shift on psychedelics positive for NRx, says D. Boral

NRx Pharmaceuticals welcomes the newly-signed Executive Order

2026-04-20T11:20:02.000Z - 2 months ago

NRx Pharmaceuticals welcomes the newly-signed Executive Order

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

Apr 20, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

Apr 15, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

Apr 13, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

Apr 6, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

NRx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q4 2025

NRx Pharmaceuticals Earnings release: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Earnings release: Q4 2025

NRx Pharmaceuticals Annual report: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Annual report: Q4 2025

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Mar 24, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

NRx Pharmaceuticals Transcript: AGM 2026

Mar 23, 2026, 10:00 AM EDT - 3 months ago

NRx Pharmaceuticals Transcript: AGM 2026

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

Mar 19, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

Mar 17, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Mar 16, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

Mar 9, 2026, 7:00 AM EDT - 4 months ago

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

Mar 2, 2026, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing

NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 23, 2026, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Feb 17, 2026, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 13, 2026, 7:00 AM EST - 5 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

Jan 16, 2026, 7:03 AM EST - 6 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

Jan 14, 2026, 7:03 AM EST - 6 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

Jan 5, 2026, 6:57 AM EST - 6 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Dec 18, 2025, 7:05 AM EST - 7 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

NRx Pharmaceuticals Registration statement: Registration Filing

Dec 12, 2025, 7:00 AM EST - 7 months ago

NRx Pharmaceuticals Registration statement: Registration Filing

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

Dec 3, 2025, 7:00 AM EST - 7 months ago

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

NRx Pharmaceuticals Transcript: Study Update

Dec 2, 2025, 9:00 AM EST - 7 months ago

NRx Pharmaceuticals Transcript: Study Update

NRx Pharmaceuticals Press release: Study Update

Dec 2, 2025, 9:00 AM EST - 7 months ago

NRx Pharmaceuticals Press release: Study Update

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

Dec 2, 2025, 8:30 AM EST - 7 months ago

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Dec 2, 2025, 7:30 AM EST - 7 months ago

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

Dec 1, 2025, 8:03 AM EST - 7 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

NRx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q3 2025

NRx Pharmaceuticals Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Earnings release: Q3 2025

NRx Pharmaceuticals Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Quarterly report: Q3 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 17, 2025, 8:03 AM EST - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Nov 12, 2025, 8:31 AM EST - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

Nov 10, 2025, 8:03 AM EST - 8 months ago

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

Oct 20, 2025, 8:03 AM EDT - 9 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

NRx Pharmaceuticals Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Oct 8, 2025, 9:30 AM EDT - 9 months ago

NRx Pharmaceuticals Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

Oct 6, 2025, 8:03 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

Sep 29, 2025, 8:03 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Sep 24, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

NRx Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:30 PM EDT - 10 months ago

NRx Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

Sep 8, 2025, 8:17 AM EDT - 10 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Sep 3, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

Sep 2, 2025, 1:19 PM EDT - 10 months ago

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

Sep 2, 2025, 8:41 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Aug 27, 2025, 8:03 AM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

NRx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 11 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q2 2025

NRx Pharmaceuticals Earnings release: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 11 months ago

NRx Pharmaceuticals Earnings release: Q2 2025

NRx Pharmaceuticals Quarterly report: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 11 months ago

NRx Pharmaceuticals Quarterly report: Q2 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 18, 2025, 8:10 AM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Aug 13, 2025, 6:06 PM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

texmade2
texmade2 Jul. 4 at 2:50 PM
$NRXP Target 1: 3.26 Support Below : at 3.64
0 · Reply
Outcomes
Outcomes Jul. 4 at 9:47 AM
$IBRX $MNKD $NRXP God bless America, from WellfleetCape Cod
1 · Reply
WhereDidAllTheMoneyGo
WhereDidAllTheMoneyGo Jul. 2 at 9:01 PM
$NRXP What's that big AH spike?
0 · Reply
the_franz
the_franz Jul. 2 at 8:33 PM
$NRXP Remember when David expected the NDA for NRX-100 in February, because Osmind data needs just some "crunching". Yeah, well, the company missed his expectations then and their own expectation (June 2026) now. But they failed their first self-imposed deadline which was "early 2024" (announced late 2023) I have put some money in some biotechs. I made profits, I made losses, but I cannot remember one company which announced a submission of a NDA for nearly three years. This is fishy as hell. The silence, why the self-imposed deadline has not been met, is deafening. Again! As someone who follows this company since its SPAC this pattern is well-known.
1 · Reply
Paulisdead
Paulisdead Jul. 2 at 6:57 PM
$NRXP If you’re evaluating NRXP as an investment, I can prepare a similar table for NRX-100, whose approval timeline has generated considerably more debate than KETAFREE’s. One important clarification before diving into the timeline: NRX-100 has undergone a significant evolution in its regulatory strategy. Earlier in development, NRX-100 referred primarily to intravenous ketamine for suicidal bipolar depression, often as the induction therapy preceding NRX-101. More recently, NRx has repositioned NRX-100 as a standalone preservative-free ketamine product with a broader depression indication supported by existing clinical trials and real-world evidence. That makes its regulatory history more complicated than KETAFREE’s.
2 · Reply
Paulisdead
Paulisdead Jul. 2 at 6:49 PM
$NRXP Asked ChatGPT How many times has the company with ticker symbol NRXP issued guidance that the fda would approve KETAFREE ketamine Answer: Based on the company’s public statements, the answer depends on how narrowly you define “guidance.” If you mean instances where NRx Pharmaceuticals (NASDAQ: NRXP) publicly indicated that it expected FDA approval of KETAFREE or provided a timeline implying approval, I can identify about five distinct guidance events: 1) Management repeatedly indicated it expected FDA action in Q2 2025 for its preservative-free ketamine program, based on its then-current regulatory strategy. That timeline ultimately slipped. 2) September 24, 2025 * After the FDA granted its Suitability Petition, the company stated this enabled immediate refiling of the ANDA and expressed confidence that KETAFREE would move toward market. <more in the reply to my post>
1 · Reply
fuctonfauci
fuctonfauci Jul. 2 at 5:45 PM
$NRXP If management says we're going to acquire the clinics and submit the NDA, then that's what we'll do. February, not Friday.
0 · Reply
TheRealBomb
TheRealBomb Jul. 2 at 1:29 PM
$NRXP @DavidBG That makes sense. The important part:. For now, the company is more than fully funded, allowing all operations and plans to go forward at full speed; and getting the ANDA to propel into profitability while awaiting the final NDA submission (NRX-100), and the running of the NRX-101/TMS trial (another massive revenue possibility) .
1 · Reply
DavidBG
DavidBG Jul. 2 at 1:19 PM
$NRXP It seems to me that NRXP is most likely still working with the FDA on a protocol for the Osmind data. That kind of back-and-forth can easily take more rounds than expected.
0 · Reply
systemish
systemish Jul. 2 at 4:53 AM
$NRXP So moving on from the missed deadline for NRX-100 NDA. It would be great to confirm that the initial order of KETAFREE is beyond initiating and is manufactured and waiting for its quarantine and testing so if approved more delays can be minimized. If not approved we’ll see all time lows and possibly bankruptcy. July going to be a wild ride.
1 · Reply
ETAlpha
ETAlpha Jul. 1 at 9:09 PM
Biotech is moving into the AI cycle. $NRXP is seeing high analyst price targets with a minimum upside potential of 511%, an average of 835%, and a maximum of 1098%. These small caps remain high risk and high reward.
0 · Reply
Rolo2024
Rolo2024 Jul. 1 at 8:20 PM
$NRXP Buy the dip! Accumulate while you can upward trajectory in the works!
1 · Reply
BioRich
BioRich Jul. 1 at 4:42 PM
$GPCR Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) $VNDA 22) $SHAZ 23) $NRXP 24) GPCR 25) $EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
dcrmia
dcrmia Jul. 1 at 4:27 PM
$NRXP Coming...🚀🔋
0 · Reply
nick_m
nick_m Jul. 1 at 4:20 PM
$NRXP this is only for value long term investors 🚀🚀🚀
2 · Reply
retired24
retired24 Jul. 1 at 4:19 PM
$NRXP 4 weeks away from the FDA decision
1 · Reply
fuctonfauci
fuctonfauci Jul. 1 at 3:47 PM
$NRXP Business as usual: management is creating value for short sellers and institutions.
1 · Reply
texmade2
texmade2 Jul. 1 at 2:55 PM
$NRXP 3.70 looks right
0 · Reply
Chumpchange53
Chumpchange53 Jul. 1 at 10:37 AM
$NRXP $NRX Pharmaceuticals Inc NRx Pharmaceuticals On July 29, 2026, the FDA is scheduled to announce its decision on NRx Pharmaceuticals, Inc.’s (NRXP) Abbreviated New Drug Application (ANDA) for KETAFREE. KETAFREE is a preservative-free intravenous ketamine formulation intended for all currently approved ketamine indications and manufactured in the United States, supporting national efforts to strengthen the domestic supply of critical medicines. Current ketamine products are typically supplied in multi-dose vials that contain a preservative called Benzethonium Chloride (BZT) that is not recognized as safe by the FDA and is banned from hand cleansers and topical antiseptics. NRXP closed Tuesday’s (June 30, 2026) trading at $4.09, up 2.25%.
1 · Reply
Rolo2024
Rolo2024 Jul. 1 at 4:34 AM
$NRXP We have huge potential catalyst that can let NRXP rip upwards and investors dump their shares on a news article about a lawsuit?! Who do you think bought you cheap shares?
2 · Reply
surfsup11
surfsup11 Jul. 1 at 2:58 AM
$NRXP So you have invested 25,000 shares at what 3.00 a share so 75,000$ in a con artist. Better have your head checked? Talk about pins and needles every morning at 7am???🤣
1 · Reply
jonny80s
jonny80s Jun. 30 at 7:36 PM
$NRXP I understand the NDA missing. I’ve known Javitt has never had the right trial data for years. But to misslead investors concerning the clinic acquisitions as well is a terrible look. 0 accountability from Javitt and his executive team: who don’t have much, if any, of stake in the organization.
2 · Reply